share_log

6-K: AstraZeneca Invests $3.5 Billion in US

6-K: AstraZeneca Invests $3.5 Billion in US

6-K:阿斯利康在美国投资35亿美元
美股SEC公告 ·  2024/11/12 22:28

Moomoo AI 已提取核心信息

AstraZeneca has announced a $3.5 billion capital investment in the United States to expand its research and manufacturing capabilities by the end of 2026. The investment includes $2 billion in new funding that will create over 1,000 high-skilled jobs, focusing on establishing a state-of-the-art R&D center in Cambridge, Massachusetts, next-generation biologics facility in Maryland, cell therapy manufacturing on both coasts, and specialty manufacturing in Texas.The investment aligns with AstraZeneca's Ambition 2030 strategy to achieve $80 billion in Total Revenue by 2030, with particular emphasis on accelerating development in the United States, which currently generates 44% of the company's total revenue. The company maintains a significant US presence with approximately 17,800 employees across 17 R&D, manufacturing, and commercial sites in 12 states.
AstraZeneca has announced a $3.5 billion capital investment in the United States to expand its research and manufacturing capabilities by the end of 2026. The investment includes $2 billion in new funding that will create over 1,000 high-skilled jobs, focusing on establishing a state-of-the-art R&D center in Cambridge, Massachusetts, next-generation biologics facility in Maryland, cell therapy manufacturing on both coasts, and specialty manufacturing in Texas.The investment aligns with AstraZeneca's Ambition 2030 strategy to achieve $80 billion in Total Revenue by 2030, with particular emphasis on accelerating development in the United States, which currently generates 44% of the company's total revenue. The company maintains a significant US presence with approximately 17,800 employees across 17 R&D, manufacturing, and commercial sites in 12 states.
阿斯利康宣布将在美国投资35亿人民币,用于扩展其研究和制造能力,计划在2026年底之前完成。此次投资包括20亿人民币的新资金,将创造1,000多个高技能就业机会,重点是在马萨诸塞州的剑桥建立一个最先进的研发中心,在马里兰州建立下一代生物制品设施,在两个海岸进行电芯疗法制造,以及在德克萨斯州进行特色制造。此次投资与阿斯利康的2030年雄心策略相一致,目标到2030年实现800亿人民币的总营业收入,特别强调加速在美国的发展,当前美国市场占公司总营业收入的44%。公司在美国保持着显著的存在,大约有17,800名员工分布在12个州的17个研发、制造和商业地点。
阿斯利康宣布将在美国投资35亿人民币,用于扩展其研究和制造能力,计划在2026年底之前完成。此次投资包括20亿人民币的新资金,将创造1,000多个高技能就业机会,重点是在马萨诸塞州的剑桥建立一个最先进的研发中心,在马里兰州建立下一代生物制品设施,在两个海岸进行电芯疗法制造,以及在德克萨斯州进行特色制造。此次投资与阿斯利康的2030年雄心策略相一致,目标到2030年实现800亿人民币的总营业收入,特别强调加速在美国的发展,当前美国市场占公司总营业收入的44%。公司在美国保持着显著的存在,大约有17,800名员工分布在12个州的17个研发、制造和商业地点。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息